GLAXOSMITHKLINE (GSK) has confirmed that its manufacturing operations will cease next year as its current contract with a ...

GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US. The programme represents the largest capital spend by ...

The funding, which brings GSK’s expenditure in US manufacturing capabilities close to $1.3bn, will establish a new vaccines ...

GSK is making its largest investment in U.S. manufacturing, committing $800 million to expand a site in Marietta, Pennsylvania with new drugmaking facilities. One will handle production of ...

In 2022, GSK’s 12 manufacturing sites in eight countries produced and delivered more than 500 million vaccine doses—one and a half million vaccine doses daily. Each year, about 40% of the ...

GSK has filed a pair of lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). According to court documents, the ...

but we don't expect heavy generic competition for this product given the complexities of vaccine manufacturing. Also, GSK’s operating structure allows for cost-cutting following patent losses to ...

A global leader in pharmaceuticals, GSK’s mechanical engineers are responsible for projects from the design and installation of manufacturing equipment through to building maintenance and R&D. As ...

The partnership, announced in April 2019, established Neopharma as GSK's third-party manufacturer for handling the Secondary Packaging process (the final manufacturing stage) for six of GSK's most ...

Working out of 12 manufacturing sites, the company distributed 767 million vaccine doses across more than 160 countries in 2021. More than ten million people received one of GSK’s meningococcal ...

In the meantime, Sanofi and GSK are scaling up manufacturing to produce up to one billion doses a year overall. Coronavirus vaccine: How close are you to getting one? The vaccine has already been ...